IP Library › Granted Patent US 12,527,742
Granted Patent B2
US 12,527,742 · App. 16/617,016 · Granted Jan 20, 2026

Methods for manufacturing a liposome encapsulated RNA

Inventors: Laurent Bernard Jean Strodiot (Rixensart, BE); Geraldine Minet (Rixensart, BE)
Assignee: GlaxoSmithKline Biologicals S.A.
A61K9/1277A61K9/1272A61K31/7105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,742
App. No.
16/617,016
Granted
Jan 20, 2026
Kind
B2
Abstract

Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.

Claims (51)

1 . A method of manufacturing a delivery system with a microfluidic device; the delivery system comprising a liposome and ribonucleic acid (RNA) molecules; the RNA molecules encoding an immunogen; the liposomes comprising lipids; the lipids comprising an ionizable cationic lipid; the liposome encapsulating at least half of the RNA molecules by mass; the microfluidic device comprising:

(i) a mixing chamber;

(ii) a first inlet into the mixing chamber, the first inlet into the mixing chamber being for delivery of a first solution into the mixing chamber, the first solution comprising an organic solvent and the lipids;

(iii) a second inlet into the mixing chamber, the second inlet into the mixing chamber being for delivery of a second solution into the mixing chamber, the second solution comprising the RNA molecules and an aqueous solution; and

(iv) an outlet out of the mixing chamber,

wherein the direction of flow of each of the first solution and the second solution into the mixing chamber is within 10 degrees of the direction of flow through the mixing chamber;

the method comprising:

(i) mixing in the mixing chamber the first solution and second solution, thereby obtaining a mixed material, the mixed material comprising the delivery system and the organic solvent;

wherein the first solution and the second solution have a ratio between 1:1.5 and 1:3 of volume of the first solution to volume of the second solution and have a total flow rate into the mixing chamber from 8 mL per minute per mm 2 of cross-sectional area of the mixing chamber perpendicular to the direction of flow in the mixing chamber to 30 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow in the mixing chamber, and

(ii) removing the organic solvent from the mixed material.

2 . The method of claim 1 , wherein the wherein the liposome has a polydispersity of 0.3 or lower.

3 . The method of claim 1 , wherein the ionizable cationic lipid a pKa of from 5.5 to 6.7.

4 . The method of claim 1 , wherein the mixing chamber is rectangular.

5 . The method of claim 1 , wherein the ionizable cationic lipid comprises a hindered ester group; a carbonate group; or an aromatic group in the core.

6 . The method of claim 5 , wherein the ionizable cationic lipid further comprises an unhindered ester group.

7 . The method of claim 1 , wherein the mixed material is collected before further processing, and optionally before the removing the organic solvent.

8 . The method of claim 1 , wherein the microfluidic device comprises one first inlet into each mixing chamber.

9 . The method of claim 1 , wherein the RNA molecule is a self-replicating RNA molecule.

10 . The method of claim 1 , wherein the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber is from 0.6 mm 2 to 1.2 mm 2 .

11 . The method of claim 1 , wherein the first solution and the second solution have the total flow rate into the mixing chamber from 12 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber to 28 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber.

12 . The method of claim 1 , wherein the cross-sectional area of the mixing chamber is from 0.6 mm 2 to 1.2 mm 2 and the first solution and the second solution have the total flow rate into the mixing chamber is from 12 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber to 28 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber.

13 . The method of claim 1 , wherein the first solution comprises from 1 mg of the lipids per mL of the organic solvent to 10 mg of the lipids per mL of the organic solvent.

14 . The method of claim 13 , wherein the organic solvent comprises ethanol and less than 30% water.

15 . The method of claim 1 , wherein the lipids further comprise a sterol, a polyethylene glycol conjugated lipid, and a zwitterionic lipid.

16 . A method of manufacturing a delivery system with a microfluidic device; the delivery system comprising a liposome and ribonucleic acid (RNA) molecules; the liposome comprising lipids; the lipids comprising an ionizable cationic lipid; the liposome encapsulating at least half of the RNA molecules by mass; the RNA molecules encoding an immunogen; the microfluidic device comprising a plurality of mixing units; each mixing unit comprising:

(i) a mixing chamber

(ii) a first inlet into the mixing chamber,

(iii) a second inlet into the mixing chamber; and

(iv) an outlet out of the mixing chamber,

wherein:

(A) each first inlet into each mixing chamber is for delivery of a first solution into each mixing chamber; the first solution comprising an organic solvent and the lipids; the first solution being supplied to the plurality of the mixing units by a first pump;

(B) each second inlet into each mixing chamber is for delivery of a second solution into each mixing chamber; the second solution comprising the RNA molecules and an aqueous solution; the second solution being supplied to the plurality of the mixing units by a second pump; and

(C) the direction of flow of each of the first solution and the second solution into each mixing chamber is within 10 degrees of the direction of flow through the mixing chamber;

the method comprising:

(i) mixing in a plurality of the mixing chambers the first solution and the second solution, thereby obtaining a mixed material, the mixed material comprising the delivery system and the organic solvent:

wherein the first solution and the second solution have a ratio between 1:1.5 and 1:3 of volume of the first solution to volume of the second solution and have a total flow rate into each mixing chamber from 8 mL per minute per mm 2 of cross-sectional area of the mixing chamber perpendicular to the direction of flow in the mixing chamber to 30 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow in the mixing chamber, and

(ii) removing the organic solvent from the mixed material.

17 . The method of claim 16 , wherein the wherein the liposome has a polydispersity of 0.3 or lower.

18 . The method of claim 16 , wherein the ionizable cationic lipid has a pKa of from 5.5 to 6.7.

19 . The method of claim 16 , wherein each mixing chamber is rectangular.

20 . The method of claim 16 , wherein the ionizable cationic lipid comprises a hindered ester group; a carbonate group; or a aromatic group in the core.

21 . The method of claim 20 , wherein the ionizable cationic lipid further comprises an unhindered ester group.

22 . The method of claim 16 , wherein the mixed material is collected before further processing; and optionally before the removing the organic solvent.

23 . The method of claim 16 , wherein each mixing unit has one first inlet into each mixing chamber.

24 . The method of claim 16 , wherein the RNA molecule is a self-replicating RNA molecule.

25 . The method of claim 16 , wherein the cross-sectional area of each mixing chamber perpendicular to the direction of flow through the mixing chamber is from 0.6 mm 2 to 1.2 mm 2 .

26 . The method of claim 16 , wherein the first solution and the second solution have the total flow rate into each mixing chamber from 12 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber to 28 mL per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber.

27 . The method of claim 16 , wherein the cross-sectional area of each mixing chamber perpendicular to the direction of flow through the mixing chamber is from 0.6 mm 2 to 1.2 mm and the first solution and the second solution have the total flow rate into each mixing chamber from 12 per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber to 28 per minute per mm 2 of the cross-sectional area of the mixing chamber perpendicular to the direction of flow through the mixing chamber.

28 . The method of claim 16 , wherein the first solution comprises from 1 mg of the lipids per mL of the organic solvent to 10 mg of the lipids per mL of the organic solvent.

29 . The method of claim 28 , wherein the organic solvent comprises ethanol and less than 30% water.

30 . The method of claim 16 , wherein the lipids further comprise a sterol, a polyethylene glycol conjugated lipid, and a zwitterionic lipid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2025
From: STRODIOT, LAURENT; MINET, GERALDINE
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 073239/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2025
From: STRODIOT, LAURENT; MINET, GERALDINE
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 073239/0516 →
Continuity (2)
Provisional Application 62512501 · May 30, 2017
Related Publication 20210128474A1 · May 6, 2021
References Cited (141)
US 6113918A · Johnson et al. · 2000 [cited by applicant]
US 6846489B1 · Garcon et al. · 2005 [cited by applicant]
US 7998913B2 · Numajiri · 2011 [cited by applicant]
US 8563325B1 · Bartsch et al. · 2013 [cited by applicant]
US 8608114B2 · Smith et al. · 2013 [cited by applicant]
US 8722064B2 · Reed et al. · 2014 [cited by applicant]
US 9168645B2 · Wassenhoven et al. · 2015 [cited by applicant]
US 9198645B2 · Jahn et al. · 2015 [cited by applicant]
US 9750812B2 · Ali et al. · 2017 [cited by applicant]
US 11243494B2 · Mueth et al. · 2022 [cited by applicant]
US 11844828B2 · Bertaud et al. · 2023 [cited by applicant]
US 20010053365A1 · Friede et al. · 2001 [cited by applicant]
US 20020097633A1 · O'Connor et al. · 2002 [cited by applicant]
US 20020098122A1 · Singh · 2002 [cited by examiner]
US 20050112184A1 · Jahn et al. · 2005 [cited by applicant]
US 20070242560A1 · Norikane et al. · 2007 [cited by applicant]
US 20100022007A1 · Kenis et al. · 2010 [cited by applicant]
US 20100182868A1 · Woehl · 2010 [cited by applicant]
US 20100202928A1 · Gaitan et al. · 2010 [cited by applicant]
US 20110212167A1 · Ali et al. · 2011 [cited by applicant]
US 20120276209A1 · Cullis · 2012 [cited by examiner]
US 20120321694A1 · Larocque et al. · 2012 [cited by applicant]
US 20130119570A1 · Sugiura et al. · 2013 [cited by applicant]
US 20130168885A1 · Omiatek · 2013 [cited by examiner]
US 20130195969A1 · Geall et al. · 2013 [cited by applicant]
US 20130202684A1 · Geall · 2013 [cited by examiner]
US 20150017191A1 · Fox et al. · 2015 [cited by applicant]
US 20150110854A1 · Shaw et al. · 2015 [cited by applicant]
US 20150115488A1 · Hood et al. · 2015 [cited by applicant]
US 20150182461A1 · Kim · 2015 [cited by examiner]
US 20160051954A1 · Brujic et al. · 2016 [cited by applicant]
US 20160214103A1 · Cullis et al. · 2016 [cited by applicant]
US 20160276209A1 · Usenko · 2016 [cited by applicant]
US 20160324783A1 · Fox et al. · 2016 [cited by applicant]
US 20160361411A1 · Gindy et al. · 2016 [cited by applicant]
US 20170071967A1 · Dutta et al. · 2017 [cited by applicant]
US 20170144123A1 · Tabeling et al. · 2017 [cited by applicant]
US 20170333348A1 · Kim et al. · 2017 [cited by applicant]
US 20210069321A1 · Schneider-Ohrum et al. · 2021 [cited by applicant]
US 20210128474A1 · Strodiot et al. · 2021 [cited by applicant]
US 20210162042A1 · Harvengt et al. · 2021 [cited by applicant]
US 20220032247A1 · Buesink et al. · 2022 [cited by applicant]
US 20220339282A1 · Harvengt et al. · 2022 [cited by applicant]
US 20230172858A1 · Castellanos Mantilla et al. · 2023 [cited by applicant]
US 20230277657A1 · Jehoulet et al. · 2023 [cited by applicant]
CN 1480136A · 2004 [cited by applicant]
CN 102133186A · 2011 [cited by applicant]
CN 102302453A · 2012 [cited by applicant]
CN 102327224A · 2012 [cited by applicant]
CN 103796642A · 2014 [cited by applicant]
CN 106902081A · 2017 [cited by applicant]
EP 1473084A2 · 2004 [cited by applicant]
EP 1810746A1 · 2007 [cited by applicant]
EP 2596858A1 · 2013 [cited by applicant]
EP 2364720B1 · 2014 [cited by applicant]
EP 2759344A2 · 2014 [cited by applicant]
FR 3043919A1 · 2017 [cited by applicant]
JP 2008163010A · 2008 [cited by applicant]
WO WO9633739A1 · 1996 [cited by applicant]
WO WO9815287A1 · 1998 [cited by applicant]
WO WO0007621A2 · 2000 [cited by applicant]
WO WO2005103106A1 · 2005 [cited by applicant]
WO WO2005112991A2 · 2005 [cited by applicant]
WO WO2007062831A1 · 2007 [cited by applicant]
WO WO2009136300A2 · 2009 [cited by applicant]
WO WO2010142685A1 · 2010 [cited by applicant]
WO WO2010142686A1 · 2010 [cited by applicant]
WO 2011140627A1 · 2011 [cited by applicant]
WO 2012030901A1 · 2012 [cited by applicant]
WO WO2013041572A1 · 2013 [cited by applicant]
WO WO2015063710A1 · 2015 [cited by applicant]
WO 2015095340A1 · 2015 [cited by applicant]
WO WO2015095346A1 · 2015 [cited by examiner]
WO WO2015148764A1 · 2015 [cited by applicant]
WO 2016037053A1 · 2016 [cited by applicant]
WO WO2016138175A1 · 2016 [cited by examiner]
WO WO2017097783A1 · 2017 [cited by applicant]
WO WO2017200957A1 · 2017 [cited by applicant]
WO WO2018219521A1 · 2018 [cited by applicant]
WO WO2018220553A1 · 2018 [cited by applicant]
Shyam Garg, Gesine Heuck, Shell Ip and Euan Ramsay. “Microfluidics: a transformational tool for nanomedicine development and production.” Journal of Drug Targeting, vol. 24, No. 9, 2016, pp. 821-835. (Year: 2016). [cited by examiner]
Alex K. K. Leung, Yuen Yi C. Tam, Sam Chen, Ismail M. Hafez, and Pieter R. Cullis. “Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems.” The Journal of Physical Chemistr… [cited by examiner]
Svetlana Ignatova et al. “Feasibility of scaling from pilot to process scale.” Journal of Chromatography A, 1151 (2007) pp. 20-24. (Year: 2007). [cited by examiner]
Hind Mamoun Beheiry et al. “Effect of pre-eclampsia on glomerular filtration rate in Sudanese women.” International Journal of Research in Medical Sciences, vol. 5 Issue 3, Mar. 2017, pp. 1053-1057. (Year: 2017). [cited by examiner]
Gujrati, et al. “Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery” Bioconjugate Chemistry; 2015; pp. 19-35; vol. 27(1). [cited by applicant]
“Lab-on-a-Chip Catalogue,” Microfluidic ChipShop GmbH, Jan. 2018, 294 pages total. [cited by applicant]
“Lab-on-a-Chip Catalogue,” Microfluidic ChipShop GmbH, Oct. 2016, 246 pages total. [cited by applicant]
Arias et al., “Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140,” PLoS One, vol. 7, Issue 7, e41144, Jul. 2012, pp. 1… [cited by applicant]
Black et al., “Developing vaccines for an aging population,” Science Translational Medicine, vol. 7, Issue 281, 281ps8, Apr. 1, 2015, pp. 1-7. [cited by applicant]
Coler et al., “Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant,” PLoS One, vol. 6, Issue 1, e16333, Jan. 2011, pp. 1-12. [cited by applicant]
Dalsgaard, “Saponin adjuvants: III. Isolation of a substance from Quillaja saponaria molina with adjuvant activity in foot-and-mouth disease vaccines,” Archiv für die gesamte Virusforschung, vol. 44, 1974, pp. 243-254. [cited by applicant]
Damiati et al., “Microfluidic devices for drug delivery systems and drug screening,” Genes, vol. 9, No. 103, 2018, pp. 1-24. [cited by applicant]
De Becker et al., “The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells,” International Immunology, vol. 12, No. 6, 2000, pp. 807-815. [cited by applicant]
Dendouga et al., “Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice,” Vaccine, vol. 30, 2012, pp. 3126-3135. [cited by applicant]
Didierlaurent et al., “Adjuvant system AS01: helping to overcome the challenges of modern vaccines,” Expert Review of Vaccines, vol. 16, No. 1, 2017, pp. 55-63. [cited by applicant]
Didierlaurent et al., “Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells,” The Journal of Immunology, vol. 193, No. 4, 2014, pp. 1920-1930. [cited by applicant]
Dillon et al., “Molecular characterization and human T-cell responses to a member of a novel [cited by applicant]
Fochesato et al., “Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine,” Human Vaccines & Immunotherapeutics, vol. 12, No. 8, 2016, pp. 20… [cited by applicant]
Fung et al., “Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity,” Journal of Nanobiotechnology, vol. 11, No. 43, 2013, pp. 1-12. [cited by applicant]
Garcon et al., “Recent clinical experience with vaccines using MPL-and QS-21-containing adjuvant systems,” Expert Review of Vaccines, vol. 10, No. 4, 2011, pp. 471-486. [cited by applicant]
Geall et al., “Nonviral delivery of self-amplifying RNA vaccines,” Proceedings of the National Academy of Sciences, vol. 109, No. 36, Sep. 4, 2012, pp. 14604-14609. [cited by applicant]
Haumont et al., “Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells,” Virus Research, vol. 40, 1996, pp. 199-204. [cited by applicant]
Helmminen et al., “A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model,” Infection and Immunity, vol. 61, No. 5, May 199… [cited by applicant]
Hood et al., “High-throughput continuous flow production of nanoscale liposomes by microfluidic vertical flow focusing,” Small, vol. 11, No. 43, 2015, pp. 5790-5799. [cited by applicant]
Ismaili et al. “Monophosphoryl lipid A activates both human dendritic cells and T cells,” The Journal of Immunology, vol. 168, No. 2, 2002, pp. 926-932. [cited by applicant]
Jahn et al., “Microfluidic directed formation of liposomes of controlled size,” Langmuir, vol. 23, No. 11, 2007, pp. 6289-6293. [cited by applicant]
Javaid et al., “Analysis of passive mixing in a serpentine microchannel with sinusoidal side walls,” Micromachines, vol. 9, No. 8, 2018, pp. 1-15. [cited by applicant]
Jeffs et al., “A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA,” Pharmaceutical Research, vol. 22, No. 3, Mar. 2005, pp. 362-372. [cited by applicant]
Joshi et al., “Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs,” International Journal of Pharmaceutics, vol. 514, 2016, pp. 160-168. [cited by applicant]
Karthikeyan et al., “Numerical modeling and parametric optimization of micromixer for low diffusivity fluids,” International Journal of Chemical Reactor Engineering, 20160231, 2018, pp. 1-11. [cited by applicant]
Kastner et al., “High-throughput manufacturing of size-tuned liposomes by a new microfluidics method using enhanced statistical tools for characterization,” International Journal of Pharmaceutics, vol. 477. 2015, pp. 36… [cited by applicant]
Kensil et al., “QS-21: a water-soluble triterpene glycoside adjuvant,” Expert Opinion on Investigational Drugs, vol. 7, No. 9, 1998, pp. 1475-1482. [cited by applicant]
Kensil et al., “Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex,” The Journal of Immunology, vol. 146, No. 2, Jan. 15, 1991, pp. 431-437. [cited by applicant]
Kim et al., “Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices,” Nano Letters, vol. 12, published Jun. 20, 2012, Correction published Sep. 17, 2013, pp. 3587-3591. [cited by applicant]
Lambrecht et al., “Mechanism of action of clinically approved adjuvants,” Current Opinion in Immunology, vol. 21, 2009, pp. 23-29. [cited by applicant]
Leroux-Roels et al., “A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults,” The Journal of Infectious Diseases, vol. 2… [cited by applicant]
Li et al., “Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3,” The Journal of Immunology, vol. 181, No. 1, 2008, pp. 17-21. [cited by applicant]
Liang et al., “Simulation and Experiment of Capillary Driven Passive Planar Baffle Micro-mixer,” Proceedings of the 10th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, Apr. 7-11, 2015, pp.… [cited by applicant]
Livingston et al., “Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma,” Vaccine, vol. 12, No. 14, 1994, pp. 1275-1280. [cited by applicant]
Martin et al., “Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A,” Infection and Immunity, vol. 71, No. 5, May 2003, pp. 2498-2507. [cited by applicant]
Marty-Roix et al., “Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants,” Journal of Biological Chemistry, vol. 291, No. 3, Jan. 15, 2016, pp. 1123-1136. [cited by applicant]
Mata-Haro et al., “The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4,” Science, vol. 316, Jun. 15, 2007, pp. 1628-1632. [cited by applicant]
McLellan et al. “Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody,” Science, vol. 340, No. 6136, May 31, 2013, pp. 1113-1117. [cited by applicant]
McLellan et al., “Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus,” Science, vol. 342, No. 6158, Nov. 1, 2013, pp. 592-598. [cited by applicant]
Meijer et al., “Passive and active mixing in microfluidic devices,” Macromolecular Symposia, vol. 279, 2009, pp. 201-209. [cited by applicant]
Newman et al., “Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses,” Journal of Immunology, vol. 148, No. 8, Apr. 15, 1992, pp. 2357-2362. [cited by applicant]
Perrie et al., “Designing liposomal adjuvants for the next generation of vaccines,” Advanced Drug Delivery Reviews, vol. 99, 2016, pp. 85-96. [cited by applicant]
Perrie et al., “Microfluidics production of liposomes—from low solubility drugs to vaccines,” Nanomedicines: Materials, Manufacturing and Therapeutic Applications, Jul. 16, 2016, 42 pages total. [cited by applicant]
Ragupathi et al., “Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer,” Expert Review of Vaccines, vol. 10, No. 4, Apr. 2011, pp. 463-470 (14 pages total). [cited by applicant]
Rasouli et al., “Numerical study on low Reynolds mixing of T-shaped micro-mixers with obstacles,” Trans. Phenom. Nano Micro Sales, vol. 3, No. 2, 2015, pp. 68-76. [cited by applicant]
Rigter et al., “A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles,” PLoS One, vol. 8, Issue 8, e71072, Aug. 2013, pp. 1-14. [cited by applicant]
Skeiky et al., “Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of [cited by applicant]
Skeiky et al., “Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein,” The Journal of Immunology, vol. … [cited by applicant]
Soltysik et al., “Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function,” Vaccine, vol. 13, No. 15, 1995, pp. 1403-1410. [cited by applicant]
Vafai, “Antibody-binding sites on truncated forms of varicella-zoster virus gpl(gE) glycoprotein,” Vaccine, vol. 12, No. 14, 1994, pp. 1265-1269. [cited by applicant]
Vladisavljevic et al. “Industrial lab-on-a-chip: Design, applications and scale-up for drug discovery and delivery,” Advanced Drug Delivery Reviews, vol. 65, 2013, pp. 1626-1663. [cited by applicant]
Yu et al., “Microfluidic Methods for Production of Liposomes,” Methods in Enzymology, vol. 465, Chapter 7, 2009, pp. 129-141. [cited by applicant]
International Search Report for International Application No. PCT/IB2018/053850, mailed Sep. 14, 2018, 4 Pages. [cited by applicant]
International Search Report for International Application No. PCT/IB2020/053044, mailed Nov. 16, 2020, 3 Pages. [cited by applicant]
Written Opinion for International Application No. PCT/IB2018/053850, mailed Sep. 14, 2018, 6 Pages. [cited by applicant]
Written Opinion for International Application No. PCT/IB2020/058044, mailed Nov. 16, 2020, 6 Pages. [cited by applicant]